{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:40:32Z","timestamp":1787168432151,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jctube.2020.100192","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T03:57:22Z","timestamp":1600747042000},"page":"100192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: A report of 12 cases"],"prefix":"10.1016","volume":"21","author":[{"given":"Innocent","family":"Murhula Kashongwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fina","family":"Mawete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Anshambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Maingowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Aloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Lukaso L'osenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Kaswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharie","family":"Munogolo Kashongwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2020.100192_b0005","unstructured":"World Health Organization. WHO treatment guidelines for multidrug and rifampicin-resistant tuberculosis, 2018 Update. Geneva Switzerland: World Health Organization; 2018."},{"issue":"3","key":"10.1016\/j.jctube.2020.100192_b0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/trstmh\/trv107","article-title":"Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings","volume":"110","author":"Sloan","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.jctube.2020.100192_b0015","doi-asserted-by":"crossref","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.jctube.2020.100192_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/jgid.jgid_125_17","article-title":"The threat of multidrug-resistant tuberculosis","volume":"10","author":"Paul","year":"2018","journal-title":"J Global Infect Dis"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09031936.00101814","article-title":"Multidrug-resistant tuberculosis around the world: what progress has been made?","volume":"45","author":"Falzon","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jctube.2020.100192_b0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccm.2009.08.015","article-title":"Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control","volume":"30","author":"Migliori","year":"2009","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.jctube.2020.100192_b0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ccm.2009.08.019","article-title":"Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and Children","volume":"30","author":"Schaaf","year":"2009","journal-title":"Clin Chest Med"},{"issue":"5","key":"10.1016\/j.jctube.2020.100192_b0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5588\/ijtld.14.0739","article-title":"Changes in treatment outcomes of multidrug-resistant tuberculosis","volume":"19","author":"Kwak","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-8-10","article-title":"Multidrug-resistant tuberculosis","volume":"8","author":"Zager","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5588\/ijtld.18.0231","article-title":"Prevalence and risk factors of multidrug-resistant tuberculosis in Cubal, Angola: a prospective cohort study","volume":"23","author":"Aznar","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5588\/ijtld.19.0173","article-title":"Multidrug-resistant tuberculosis in the United States, 2011\u20132016: patient characteristics and risk factors","volume":"24","author":"Chen","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jctube.2020.100192_b0060","unstructured":"World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug resistant tuberculosis WHO\/HTM\/TB\/2014.11. Geneva, Switzerland: WHO; 2014."},{"key":"10.1016\/j.jctube.2020.100192_b0065","unstructured":"World Health Organization. WHO treatment guideline for drug resistant tuberculosis, 2016 update. WHO\/HTM\/TB\/2016. Geneva, Switzerland: WHO; 2016."},{"key":"10.1016\/j.jctube.2020.100192_b0070","unstructured":"World Health Organisation. WHO Consolidate guidelines on drug resistant tuberculosis. Geneva, Switzerland: WHO; 2019."},{"issue":"3","key":"10.1016\/j.jctube.2020.100192_b0075","doi-asserted-by":"crossref","first-page":"1700146","DOI":"10.1183\/13993003.00146-2017","article-title":"Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline","volume":"49","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jctube.2020.100192_b0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jctube.2020.100192_b0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5588\/ijtld.18.0622","article-title":"Management of patients with multidrug-resistant tuberculosis","volume":"23","author":"Lange","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.jctube.2020.100192_b0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2020.100192_b0095","doi-asserted-by":"crossref","unstructured":"Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015;19:979\u201385. https:\/\/doi.org\/10.5588\/ijtld.14.0944.","DOI":"10.5588\/ijtld.14.0944"},{"key":"10.1016\/j.jctube.2020.100192_b0100","doi-asserted-by":"crossref","unstructured":"Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis 2019;68:1522\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy727.","DOI":"10.1093\/cid\/ciy727"},{"issue":"2","key":"10.1016\/j.jctube.2020.100192_b0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jctube.2020.100192_b0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5588\/ijtld.17.0706","article-title":"Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis","volume":"22","author":"Cox","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jctube.2020.100192_b0115","unstructured":"United Nations Development Programme. Human development reports. Democratic Republic of Congo: HDR; 2019."},{"issue":"4","key":"10.1016\/j.jctube.2020.100192_b0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5588\/ijtld.17.0741","article-title":"Treatment responses in multidrug-resistant tuberculosis in Germany","volume":"22","author":"Heyckendorf","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-016-0214-x","article-title":"Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies","volume":"6","author":"Kibret","year":"2017","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5588\/pha.16.0055","article-title":"Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India","volume":"7","author":"Nair","year":"2017","journal-title":"Public Health Action"},{"issue":"23","key":"10.1016\/j.jctube.2020.100192_b0135","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for Multidrug-Resistant Pulmonary Tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jctube.2020.100192_b0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/jgid.jgid_96_17","article-title":"Treatment outcomes associated with multidrug-resistant tuberculosis","volume":"10","author":"Gupta","year":"2018","journal-title":"J Global Infect Dis"},{"key":"10.1016\/j.jctube.2020.100192_b0145","unstructured":"World Health Organisation. Rapid communication: key changes to treatment of MDR and RR tuberculosis (MDR\/RR-TB): WHO\/HTM\/TB\/2018.18. Geneva Switzerland: WHO; 2018."},{"key":"10.1016\/j.jctube.2020.100192_b0150","doi-asserted-by":"crossref","unstructured":"Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015;19:385\u201391. https:\/\/doi.org\/10.5588\/ijtld.14.0335.","DOI":"10.5588\/ijtld.14.0335"},{"issue":"1","key":"10.1016\/j.jctube.2020.100192_b0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5588\/ijtld.19.0062","article-title":"Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose","volume":"24","author":"Hong","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"10.1016\/j.jctube.2020.100192_b0160","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ijporl.2015.04.040","article-title":"The occurrence of auditory dysfunction in children with TB receiving ototoxic medication at a TB hospital in South Africa","volume":"79","author":"Ghafari","year":"2015","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.jctube.2020.100192_b0165","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva Switzerland: World Health Organization; 2020."},{"key":"10.1016\/j.jctube.2020.100192_b0170","unstructured":"Rapidcommunication:keychangestotreatmentofdrug-resistanttuberculosis. Geneva: World Health Organization; 2019 (WHO\/CDS\/TB\/2019.26).Licence:CCBY-NC-SA3.0IGO."},{"key":"10.1016\/j.jctube.2020.100192_b0175","unstructured":"WHO consolidated guidelines on tuberculxosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO."}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579420300565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579420300565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:37:05Z","timestamp":1762501025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579420300565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":35,"alternative-id":["S2405579420300565"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2020.100192","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: A report of 12 cases","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2020.100192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100192"}}